Atlas Trials

A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies

Clinical trial NCT07294300 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07294300
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Relapsed/Refractory Hematological Malignancies
Start date
2026-01-01
Primary completion
2028-02-01
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.